DadFinStart your free week
DadFin › Stocks › Real Estate › OHI

Omega Healthcare Investors, Inc. (OHI) stock score

Real Estate · REIT - Healthcare Facilities · United States

$44.41 ▲ +0.61% today

77.0
Dad Score, out of 100
good

Omega Healthcare Investors, Inc. (OHI) is a REIT - Healthcare Facilities company in the Real Estate sector, listed in the United States. On DadFin's weekly run it scores 77.0 out of 100 on the Dad Score, a good reading that places the business ahead of 77% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Real Estate it ranks #41 of 240. Its strongest axes are valuation, quality and growth; its weakest are price action and conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Strong
Growth
Strong
Price action
Below average
Risk
Strong
Conviction
Weak
Liquidity
Strong
Macro
Strong

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)16.3×
P/E (forward)22.6×
Dividend yield5.95%
Return on capital8.7%
Operating margin61.5%
Revenue growth (YoY)+13.2%
FCF yield4.7%
Net debt / EBITDA3.51×
Piotroski F-Score7 / 9
52-week change+18.6%
Market cap$14.4B
Next earningsNov 3, 2026

What subscribers see on OHI

Start your free weekSubscriber? Open the full research →

REIT - Healthcare Facilities peers

StockCompanyDad ScoreBandMarket cap
WELLWelltower Inc.46.6middling$164.1B
VTRVentas, Inc.41.7middling$43.1B
DOCHealthpeak Properties, Inc.37.7weak$13.8B
AHRAmerican Healthcare REIT, Inc.51.5middling$11.1B
CTRECareTrust REIT, Inc.29.1weak$8.6B
SBRASabra Health Care REIT, Inc.35.0weak$4.9B
NHINational Health Investors, Inc.82.4good$3.2B
LTCLTC Properties, Inc.92.3strong$2.3B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.